Back to Research Home
GGenpact Limited
Consumer Discretionary · Professional Services · Mid
$40.83−2.27%
As of 23 Oct 2026Mkt cap $6.3B
Stage 13
WATCH
Fundamentals
59.3/75
Technical
9.7/15
Independent
69.0/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +22.4%
- 3M
- +26.9%
- 6M
- +19.0%
- 1Y
- +2.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 12.1xHist median 13.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 12.6x
- FCF yield
- 7.9%
Quality
- ROIC
- 18.3%
- Operating margin
- 14.7%
- FCF margin
- 14.5%
- Current ratio
- 1.7x
Growth
- Revenue growth
- +6.6%Latest FY YoY
- Revenue CAGR
- +6.0%
- EPS CAGR
- +13.1%
- FCF CAGR
- +3.5%
Capital
- Share-count trend
- −2.3%3Y annualised
- Net debt
- $515M0.6x OCF
Annual trend
- CAGR 2021–2025
- +6.0%
- Latest · 2025
- $5B
- YoY
- +6.6%
GCAE Research
- Quality Research
- REINFORCES
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- QUALITY OPPORTUNITY — WAIT FOR SETUP / REPAIR
Key takeaway
Fresh 24 October review found no material company-specific evidence sufficient to change the approved qualitative verdict; the stated watch items remain unresolved.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Advanced Technology Solutions growth
- Core Business Services growth
- bookings conversion and operating cash flow
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded